Articles by Leah Lawrence
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
The study "confirmed the role of adagrasib compared to docetaxel" in terms of PFS, response rate, and intracranial response.
The study findings "add critical evidence to support ongoing access to telehealth services" in these patients.
Patients with hemophilia A who received prophylaxis had a reduced risk for ICH.
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
Just under a quarter of a million new cases of lung cancer were diagnosed in 2023, with 10-20% in non-smokers.
Although most of patients with NSCLC will receive immunotherapy, a growing percentage are eligible for targeted agents.
Within the lung cancer realm, different types of AI are being applied to advance the understanding of the disease.
ESMO 2023 data reflected the fact that there are a growing number of patients with advanced NSCLC have genomic alterations.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.